Abstract：OBJECTIVE To acquire the expressing information about tumor abnormal glycoprotein (TAP) in the peripheral blood of the gastric cancer patients who are treated with fluorouracil and the colorectal cancer patients treated with fluorouracil, and to discuss the factors that affect its expression and its clinical significance. METHODS This research was conducted on the basis of 99 gastric cancer patients and colorectal cancer patients whose diseases were pathologically diagnosed from May to December, 2018, including 53 gastric cancer patients treated with fluorouracil and paclitaxel and 46 colorectal cancer patients treated with fluorouracil and oxaliplatin. It tested their TAP values, collected the basic information, the type of the cancer, the stage of the cancer, serum tumor markers, etc. of the patients as well as analyzed the differences of the expression of TAP in gastrointestinal tumors with different characteristics. RESULTS The expression value of TAP in the peripheral blood of the gastrointestinal cancer patients is (158.11±33.63), and the expression of TAP value has no statistical differences in the expression of different sexes, ages, types of the cancer, clinical stages and serum tumor markers. CONCLUSION The fact that the expression of TAP has no differences in the gastrointestinal cancer patients with different characteristics can′t be taken as the basis of identifying or diagnosing gastrointestinal tumors which are different in character.
印妮, 王雨雯, 唐雨曼, 朱彦博, 王振欣. 基于氟尿嘧啶类药物化疗的异常糖链糖蛋白在胃肠道恶性肿瘤中表达[J]. 中国药学杂志, 2019, 54(24): 2093-2096.
YIN Ni, WANG Yu-wen, TANG Yu-man, ZHU Yan-bo, WANG Zhen-xin. Clinical Study on Expression of Tumor Abnormal Glycoproteins in Patients with Gastrointestinal Malignancies after Fluorouracil-based Chemotherapy. Chinese Pharmaceutical Journal, 2019, 54(24): 2093-2096.
DUAN J J, YAN Y Q, YANG N N, et al. International comparison analysis of China′s cancer incidence and mortality[J]. Chin J Frontiers Med Sci(中国医学前沿杂志电子版), 2016, 8(7):17-23.
[2]
CHEN W Q, ZENG R S, ZENG H M, et al. Report of cancer incidence and mortality in China, 2011[J]. China Cancer(中国肿瘤), 2015, 24(1):1-10.
[3]
LI M, SONG L, QIN X. Glycan changes: cancer metastasis and anti-cancer vaccines[J]. J Biosci, 2010, 35 (4):665-673.
[4]
BING Z, LU Y, SUN L R, et al. The role of abnormal sugar chain glycoprotein in the accurrence and development of tumorigenesis and the progress of detection [J]. Qilu Med J(齐鲁医学杂志), 2015, 30(2):245-246,252.
[5]
DUBE D H, BERTOZZI C R. Glycans in cancer and inflammation--potential for therapeutics and diagnostics[J]. Nat Rev Drug Discov, 2005, 1(6):477-488.
[6]
ZHANG Q F, LI Y Z, LI J X. The value of serum CA199, CA242 and CA724 in the diagnosis of malignant tumor of digestive system [J]. J Shanxi Med Univ(山西医科大学学报), 2007(5):430-432.
[7]
JIN H, ZHAN H G, CUI X. Evaluationof the efficacy of tumor abnormal protein detection system in the detection of digestive systemtumors[J]. Mod Med(现代医学), 2006(4):270-271.
[8]
QIU Z Y, TAO S, LEI Z, et al. The clinical value of tumor abnormal protein in gastrointestinal tumor [J]. Cancer Prog(癌症进展), 2016, 14(4):340-342.
[9]
ZHAO L N, ZHANG L. The value of tumorabnormal protein in the diagnosis of head and neck tumors [J]. Zhejiang Integr Tradit Western Med(浙江中西医结合杂志), 2015, 25(9):846-847.
[10]
XU R T, XU Y L, WANG T, et al. The expression of abnormal protein in peripheral blood of patients with lung cancer and its clinical significance[J]. Cancer Prog(癌症进展), 2018, 16(13):1644-1646.
[11]
YIN Y, YAO X B, ZHAO Y R. The value of abnormal tumor protein in the diagnosis and prognosis evaluation of hepatocellular carcinoma[J]. Shanxi Med J(陕西医学杂志), 2016, 45(9):1253-1255.
[12]
YUE X G, XU X Y. The expression of tumor abnormal protein in the malignanttumor of the digestive tract and the evaluation of the curative effect [J]. J Clin Med, Elec J(临床医药文献电子杂志), 2017, 4(8):1431-1432.
2019, Vol. 54 
